

## NEWSLETTER

### CHEMICAL & PHARMACEUTICAL

27 April - 3 May 2026



#### **Celanese Raises Prices on Multiple Rubber and Plastic Products in May**

Global specialty materials giant Celanese officially announced a new round of price increases for engineering plastics. Driven by recent market developments and global supply chain disruptions, the company will raise prices for several core engineering plastic products in the Asian region. This price adjustment covers mainstream categories such as PA6/66, PET, and TPV. The new prices will officially start on May 1, 2026. **(ChemNet Chemical Headlines)**

#### **EU Imposes Provisional Anti-dumping Duties on Chinese Monosodium Glutamate (MSG)**

The European Commission issued a notice in response to an application submitted on January 18, 2026, by Ajinomoto Foods Europe SAS, an EU member state company, initiating a third sunset review investigation into anti-dumping duties on MSG originating in China. The dumping investigation period is from April 1, 2025 to March 31, 2026. **(China Trade Remedy Information Network)**

#### **Belarusian Potash Fertilizer Exports to China Increase in March**

According to the latest customs statistics, China's potash fertilizer imports showed a trend of both volume and price increases in the first quarter of this year. March saw continued growth in import volume, with Belarusian potash fertilizer exports to China maintaining a sustained upward trend, becoming an important source of China's potash fertilizer imports. **(ChemNet Chemical Headlines)**

#### **China approves its first AI-discovered drug for idiopathic pulmonary fibrosis**

China has approved the first drug whose core molecule was discovered and optimized primarily by an artificial intelligence platform. The drug, for treating idiopathic pulmonary fibrosis, was developed in a record 36 months from target identification to market approval. The approval validates China's growing capability in AI-driven pharmaceutical R&D. The therapy is projected to reach patients in the second quarter of 2026. **(National Medical Products Administration)**

#### **World's first oral mRNA vaccine for norovirus enters phase 3 trials in China**

The world's first thermostable, oral mRNA vaccine for norovirus, developed by a Chinese biotech firm, has entered Phase 3 clinical trials. The tablet-form vaccine uses novel lipid nanoparticles designed for gastrointestinal delivery. It aims to provide broad protection against the leading cause of severe viral gastroenteritis globally. **(The Lancet)**